Thyroid Cancer
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Thyroid Cancer

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Thyroid Cancer Local Doctors?
Elite in Thyroid Cancer
Elite in Thyroid Cancer

Jefferson Torresdale Hospital

10800 Knights Road, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients

Marcia Brose is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Brose is rated as an Elite provider by MediFind in the treatment of Thyroid Cancer. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Thyroid Cancer, Medullary Thyroid Carcinoma, Papillary Thyroid Cancer, and Anaplastic Thyroid Cancer. Dr. Brose is board certified in Medical Oncology. Dr. Brose is currently accepting new patients.

Elite in Thyroid Cancer
Endocrinology | Internal Medicine
Elite in Thyroid Cancer
Endocrinology | Internal Medicine

Domino's Farms

24 Frank Lloyd Wright Dr Ste 1300, Lobby C, 
Ann Arbor, MI 
Languages Spoken:
English
Offers Telehealth

Megan R. Haymart, MD is Professor of Internal Medicine with an appointment in the Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan. She holds the Nancy Wigginton Endocrinology Research Professorship of Thyroid Cancer and is Director of Thyroid Cancer Research at the University of Michigan. Dr. Haymart received her medical degree at Johns Hopkins University School of Medicine and completed her internal medicine residency at Johns Hopkins Hospital. She then completed a fellowship in endocrinology, diabetes, and metabolism at the University of Wisconsin. She has been faculty at the University of Michigan since 2009.Dr. Haymart has a history of NIH-funded research focused on optimizing thyroid care delivery. She is a health services researcher who primarily studies thyroid cancer care across the disease continuum: from the diagnosis of a thyroid nodule to cancer survivorship. In recognition of her research, she received the American Thyroid Association’s Van Meter Award for outstanding contributions to research on the thyroid gland (2017), the University of Michigan’s Jerome Conn Award for Research Excellence (2017), membership to American Society for Clinical Investigation (2018), the AACE Hossein Gharib Education Lectureship Award for exemplary contributions to an individual profession or area of expertise (2021), and the inaugural AACE Endocrine Care Innovation Award in recognition of her team’s outstanding body of work focused on clinical outcomes or health care delivery (2025).Dr. Haymart is actively involved in improving research infrastructure at the University of Michigan. This includes her roles as Assistant Director of Data Solutions for AI & Digital Health Innovation, faculty support for MICHR, and co-Director of Patient’s First. She also devotes time to mentoring junior faculty and trainees resulting in her receipt of the MICHR Distinguished Clinical and Translational Research Mentor Award (2021) and the Women in Thyroidology and American Thyroid Association Woman of the Year Award (2021) for promoting the advancement of women, both within the organization and field. Dr. Haymart is rated as an Elite provider by MediFind in the treatment of Thyroid Cancer. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Thyroid Cancer, Thyroid Nodule, Papillary Thyroid Cancer, Thyroidectomy, and Hormone Replacement Therapy (HRT). Dr. Haymart is board certified in Endocrinology, Diabetes & Metabolism.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Thyroid Cancer
Surgical Oncology | General Surgery
Elite in Thyroid Cancer
Surgical Oncology | General Surgery

University Of Pittsburgh Physicians - Endocrine Surgery

3601 5th Avenue, Falk Medical Building, Suite 6B, 
Pittsburgh, PA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Linwah Yip, MD, FACS, is an associate professor in the Department of Surgery, Division of Endocrine Surgery at the University of Pittsburgh School of Medicine, chief of the Division of Breast and Endocrine Surgery, and program director for the University of Pittsburgh  Endocrine Surgery Fellowship. She specializes in thyroid and parathyroid disease/cancers, adrenal tumors, and functional pancreatic tumors. She studies how molecular testing can optimize diagnosis and treatment for thyroid cancer patients and leads the UPMC VHL Alliance Comprehensive Clinical Care Center.Dr. Yip is board-certified in general surgery. She received her medical degree from the University of Chicago Pritzker School of Medicine, Chicago. Dr. Yip completed surgical residency training at Northwestern University in Chicago and the University of Florida Health Sciences Center in Jacksonville, Fla., and surgical oncology research and clinical fellowships at the University of Texas MD Anderson Cancer Center and UPMC. Dr. Yip is rated as an Elite provider by MediFind in the treatment of Thyroid Cancer. She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Thyroid Nodule, Thyroid Cancer, Papillary Thyroid Cancer, Thyroidectomy, and Parathyroidectomy. Dr. Yip is board certified in American Board Of Surgery. Dr. Yip is currently accepting new patients.

What are the latest Thyroid Cancer Clinical Trials?
Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions

Summary: Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an i...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...